A Clinical study to evaluate the Safety and efficacy of hyaluronic acid injection containing stromal vascular fraction extracted from adipose tissue of patients with enophthalmos

开始日期2025-01-31

申办/合作机构

Bundang CHA Hospital

CTRI/2024/11/077456

/ Not yet recruitingN/AIIT

Effectiveness of 0.1 percent Hyaluronic Acid with 0.2 percent Chlorhexidine Mouthrinse or 0.2 percent Chlorhexidine Mouthrinse alone as adjunct to scaling and root planing on clinical parameters and salivary aspartate aminotransferase marker in Periodontitis : A Prospective randomized observer blinded study - NIL

开始日期2024-12-10

申办/合作机构

Dr. Reddy's Laboratories Ltd.

IRCT20091012002576N49

/ Recruiting临床2/3期IIT

Comparisons the effect of hyaluronic acid injection in prevention of adhesions after hysteroscopy septoplasty

开始日期2024-10-22

申办/合作机构

Tehran University of Medical Sciences

100 项与透明质酸相关的临床结果

登录后查看更多信息

100 项与透明质酸相关的转化医学

登录后查看更多信息

100 项与透明质酸相关的专利（医药）

登录后查看更多信息

8,226

项与透明质酸相关的文献（医药）

2025-12-31·Future Science OA

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management

Review

作者: Vaidya, Anuradha ; Ravindran, Selvan ; Dixit, Tanu

This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.

2025-12-01·Current Pain and Headache Reports

The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review

Review

作者: Wang, Fengxian ; Li, Li ; Dou, Xiaofan ; Song, Xueliang

PURPOSE OF REVIEW:

Hip osteoarthritis constitutes a prevalent condition among individuals aged 55 and above, serving as one of the primary triggers for joint discomfort and impairment, and marking a substantial origin of chronic pain particularly affecting the elderly population. Our article provides an exhaustive summary of the mechanisms of action, therapeutic efficacy, and potential adverse consequences associated with novel therapeutic modalities including glucocorticoids, hyaluronic acid, platelet-rich plasma, mesenchymal stem cells, and stromal vascular fraction. Concurrently, we conducted a comprehensive evaluation of the clinical efficacy and potential applications of various medications.

RECENT FINDINGS:

In comparison to physical therapy, oral analgesics, and other nonsurgical modalities, intra-articular injection therapy is characterized by enhanced safety and greater efficacy. Moreover, when contrasted with surgical intervention, intra-articular injection demonstrates a lower degree of invasiveness and incurs fewer adverse reactions. Intra-articular treatments have shown excellent local efficacy while significantly minimizing adverse reactions in patients. These methods hold significant potential for development but require comprehensive research and thorough discussion within the academic community.

2025-12-01·Current Urology Reports

Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer

Review

作者: Cheung, Felix ; Ajay, Divya ; Clements, Matthew ; Pietzak, Eugene ; Seiden, Benjamin

PURPOSE OF REVIEW:

This narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.

RECENT FINDINGS:

There is sparse but promising evidence in improving LUTS secondary to intravesical therapy. Oral agents including phenazopyridine and hyaluronic acid, Bacillus Calmette-Guerin dose reduction, and emerging therapies including beta-3 agonists as well as Onabotulinumtoxin A injections all have demonstrated encouraging improvement in LUTS in limited research. Although recent literature explores new medications and potential strategies for managing intravesical therapy-related LUTS, further research is required to establish efficacy and new consensus on treatment strategies. Further research is also required to establish effective LUTS mitigation strategies with other emerging intravesical therapy regimens.

项与透明质酸相关的新闻（医药）

2025-06-25

·Cytiva学堂

透明质酸下游纯化攻略：三大核心方法深度解析与工艺选型指南

透明质酸（Hyaluronic acid，HA），是以N-已酰-D-葡萄糖胺（N-acetyl-D-glucosamine）和葡萄糖醛酸（Glucuronic acid）二糖为基本单位形成的线性黏多糖，两种单糖之间通过β-1，3-糖苷键相连，双糖单位通过β-1，4-糖苷键相连（图1）[1]。图1：透明质酸一级结构透明质酸的分子量范围较广，从低分子量（<60 kDa）到高分子量（>2000 kDa），不同分子量的透明质酸具有不同的理化性质和生物功能，低分子量透明质酸具有抗炎作用，而高分子量透明质酸则具有良好的抗氧化性和润滑关节的功能（表1）[2] 。表1：不同分子量透明质酸（HA）应用场景[3]透明质酸的获取方式包括： 1 微生物发酵法：利用链球菌等微生物发酵生产; 2 组织提取法：从动物组织（如鸡冠、牛眼玻璃体）中提取; 3 重组表达法：通过酶法或化学合成制备（表2）。表2：不同方法获取透明质酸特性比较[4]不同来源获得透明质酸需要进一步纯化处理才能满足国内外药典对透明质酸质量标准的要求（表3），本文主要介绍透明质酸下游常见纯化方法，以此为合理选择透明质酸的纯化方法提供参考依据。表3：国内外药典对透明质酸主要质量参数要求标准01· 沉淀法 ·沉淀法是透明质酸纯化中最常用的方法之一，主要包括季铵盐沉淀法和有机溶剂沉淀法。季铵盐纯化法是利用季铵盐与透明质酸在低盐条件下形成络合物沉淀，从发酵液中不断分离出来，再通过高浓度盐溶液解离，从而获得高纯度的透明质酸产品。常用的季铵盐有溴代十六烷基吡啶（CPB）、十六烷基三甲基溴化铵（CTAB）、氯代十六烷基三甲基吡（CPC）和其它长链季铵盐[5] ，该方法提纯的HA纯度较高，效果较好，能除去样品中不和季铵盐络合的杂质。有机溶剂沉淀法是通过影响介质的介电常数造成分子聚集来去除蛋白质。黄小红等采用乙醇和季铵盐相结合的方法以微生物发酵液为原料提取纯化透明质酸，研究发现采用某些表面活性剂，如十六烷基吡啶（CPC）等，与透明质酸的聚阴离子形成络合物沉淀，相比于单独用乙醇沉淀透明质酸提取效率更高（表4）[6]。表4：乙醇和乙醇与CPC结合沉淀HA的提取率的比较02· 超滤法 ·超滤法是利用超滤膜进行过滤，使不同分子量的物质获得分离，以达到清除杂质、浓缩样液以及获得高纯度产物的目的。张延良等使用中空纤维和超滤膜包利用超滤方法得到低分子量透明质酸溶液的蛋白去除率达到97%以上，透明质酸收率为83.5%[7]。作者比较不同孔径超滤产品纯化透明质酸的蛋白去除率和收率，结果发现截留分子量为10 kDa的超滤膜比较合适（表5）。表5：不同截留孔径膜包对透明质酸收率及蛋白去除率的影响研究人员进一步比较了乙醇沉淀法和超滤法获得透明质酸的质量参数和生产成本，发现乙醇沉淀法与超滤法比较，两种工艺的收率相近，但超滤工艺的蛋白去除效果较好。从生产成本来看，超滤设备的投资和乙醇工艺的成本相比，2年即就可抵消设备成本，因此长期来看超滤法具有更低的生产成本（表6）[7]。同时研究人员通过实验发现在透明质酸纯化过程中，使用中空纤维或者超滤膜包效果没有差异。表6：两种工艺的质量参数和成本对比Oueslati等使用100 KDa PES膜包纯化分子量2 MDa的透明质酸，通过10倍体积的洗滤样品透明质酸纯度从3%提高至接近100%，样品收率也接近100%[8]。需要说明的是因为透明质酸分子量分布范围较广，选择超滤膜包或者中空纤维孔径要依据具体透明质酸和需要去除杂质的分子量进行确定。Cytiva中空纤维产品和超滤膜包产品系列齐全——超滤中空纤维膜和膜包包括：1 k，3 k，5 k，10 k，30 k，50 k，100 k，300 k，500 k，750 kDa NMWC（截留分子量）；微滤中空纤维膜和膜包包括：0.1/0.2/0.45/0.65 µm（图2），产品规格可以满足从实验室到生产规模不同样品体积的需求。图2：Cytiva中空纤维柱和超滤膜包产品03· 层析色谱法 ·透明质酸纯化过程中层析色谱方法包括凝胶过滤和离子交换两种主要形式。凝胶过滤层析也称为体积排阻层析（Size Exclusion Chromatography，SEC），是根据物质分子量大小和形状的差异进行分离的层析技术。透明质酸分子结构中含有多个葡萄糖醛酸单元，使其在中性pH条件下带负电荷。这种负电荷特性使得透明质酸能够与带正电荷的阴离子交换填料（如DEAE）发生吸附作用。实践中通常把凝胶过滤和离子交换两种方法结合使用，以获得纯度更高的透明质酸。Kakizaki等使用Cytiva阴离子交换填料DEAE从鲑鱼软骨中分离出透明质酸（HA），再使用Cytiva凝胶过滤填料Sepharose CL-4B进行脱盐处理[9]。研究人员使用DEAE填料通过线性洗脱方式，大约在0.2 M NaCl浓度条件下洗脱得到透明质酸（Pool X，Frs.112–132）（图3）。图3：DEAE-Sephacel纯化透明质酸层析图谱目前，Cytiva有新一代高流速Capto骨架离子交换填料以及高分辨率分子筛填料提供，进而帮助提高透明质酸纯化的纯度与收率。✦ 总结✦以上透明质酸纯化工艺中的方法，每种方法都有不同使用场景和特点，比如季铵盐沉淀法多用于发酵液的直接沉淀；离子交换层析法和凝胶层析法是常规的制备较高纯度透明质酸的方法；超滤法同样是透明质酸纯化工艺中的常用方法。各种纯化方法不是独立排斥的，通常是多种方法配合使用，图4展示了重组表达透明质酸下游纯化工艺，使用到沉淀、过滤和层析等纯化方法[4]。图4：透明质酸的纯化过程示意图[4]除了以上纯化方法，透明质酸纯化常见方法还包括过滤法，吸附法和电泳法等，这些纯化方法各有其优缺点，实践中通常是多种纯化方法配合使用。通常需要根据具体的工艺要求和成本考虑，选择合适的纯化方法。一般过滤法和吸附法适用于初步纯化，而离子交换层析法和过滤技术则适用于进一步纯化。通过综合应用以上各种方法，可以有效提高透明质酸的纯度和收率，满足不同应用领域纯化透明质酸的需求。下期内容预告作为本文后续内容，下期将给大家带来与透明质酸降解密切相关的透明质酸酶（hyaluronidase, HAase）下游纯化相关内容，敬请关注。相关阅读：☞ Cytiva中空纤维产品特性与选择指南参考文献1.Kogan G，Soltes L，Stern R，et al.，Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications，Biotechnology Lett (2007) 29:17–252.Sze, J.H.; Brownlie, J.C.; Love, C.A. Biotechnological Production of Hyaluronic Acid: A Mini Review. 3 Biotech 2016, 6, 67.3.Boeriu, C.G.; Springer, J.; Kooy, F.K.; van den Broek, L.A.M.; Eggink, G. Production Methods for Hyaluronan. Int. J. Carbohydrate. Chem. 2013, 2013, 6249674.F. Saadati et al. Advances and principles of hyaluronic acid production, extraction，purification, and its applications: A review. International Journal of Biological Macromolecules 312 (2025) 1438395.AMAGAI I, TASHIRO Y, OGAWA H. Improvement of the extraction procedure for hyaluronan from fish eyeball and the molecular characterization[J]. Fisheries Science，2009，75（3）：806.黄小红,吴泽杰,钟志威,等.发酵液中透明质酸的分离纯化[J]. 食品研究与开发,2011,8(32):111-113.7.张延良,黄宇,张冬良.超滤技术应用于透明质酸发酵液初提工艺的研究[J]. 医学信息,2010,(7):1529-1530.8.Oueslati, N et al.: A Simple Methodology for Predicting the Performances of Hyaluronic Acid Purification by Diafiltration. J. Membr. Sci. 2015, 490, 152–159.9.Kakizaki et al.: Hot Water Cartilage Extract Proteoglycan. J. Appl. Glycosci., Vol. 64, No. 4 (2017)本期关键词：#Capto

临床研究

2025-06-11

·GlobeNewswire-Health Care

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment. WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced two bold awareness initiatives in conjunction with Men’s Health Month to raise awareness for quality-of-life issues associated with benign prostatic hyperplasia (“BPH”) and the potential rectal toxicity side effects for men who undergo a prostate cancer radiation treatment plan. The initiative includes a new ad campaign featuring the Prostate Monster, and a mobile training and education center—The Prostate Education Express—which is visiting urology practices, hospitals and academic medical centers across major U.S. cities for the remainder of 2025. These activities are focused on educating physicians and the community on the benefits of treatment with the UroLift™ System, the #1 chosen minimally invasive, outpatient treatment for symptoms of an enlarged prostate, or BPH1, and the benefits of organ spacing using the Barrigel™ rectal spacer in advance of prostate cancer radiation therapy.2 The ad campaign airing on cable networks, streaming platforms, and related digital ads, features the unforgettable “Prostate Monster,” a larger-than-life symbol of the everyday disruption BPH can cause in men’s lives—from interfering with sleep to making simple tasks like mowing the lawn or sitting in traffic uncomfortable. The ads direct viewers to UroLift.com, where men can learn more and take the first step toward relief. When the prostate grows, it can press against the urethra and block the flow of urine, leading to symptoms like frequent urination, weak stream, and interrupted sleep.3 More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.4 Despite how common BPH is, many men delay treatment. “So many men suffer silently with symptoms that can seriously affect their quality of life,” said Claus Roehrborn, M.D* professor of urology at UT Southwestern Medical Center and primary investigator on many UroLift™ System clinical studies over the past 12 years. “Men need to know they don’t have to ‘just deal with it.’ The UroLift™ System offers rapid symptom relief without the need for ongoing medications.”5,6 As a traveling classroom, training hub, and community engagement center, the Prostate Education Express provides hands-on UroLift™ System and Barrigel™ rectal spacer simulator training at a practice’s front door. The national tour will support training for general practicing physicians. The truck will also host community health talks to educate men about their prostate health and collaborate with advocacy events to amplify BPH awareness across major U.S. cities including New York City, Los Angeles, Chicago, Houston, Dallas, Atlanta, Miami, Washington, DC, San Francisco, and Philadelphia. “June is Men’s Health Month—a time to shine the spotlight on the unique health challenges men face, including BPH, a non-cancerous progressive health concern that commonly occurs as men age,” said Anthony Parrillo, vice president, Global Marketing, Teleflex Interventional Urology. “Across the U.S., 14.1 million men seek treatment for BPH symptoms annually.1 The national ad and Prostate Education Express initiatives are extensions of our mission to empower the future of healthcare by educating and motivating men to prioritize their prostate health and seek out effective, proven treatment options like the UroLift™ System5 and understand the importance of rectal organ protection in advance of prostate cancer radiation treatment with Barrigel™ rectal spacer2.” A clinical study found that 98.5 percent of men who were treated with Barrigel™ rectal spacer met the primary endpoint of achieving at least a 25 percent reduction in radiation to the rectum.2 Patients who met the primary endpoint averaged an 85 percent reduction in radiation to the rectum, and Barrigel™ rectal spacer is proven superior in the reduction of acute and long-term Grade 2+ GI toxicity at 3 and 6 months compared to control.2 More than 50,000 men have been treated with Barrigel™ rectal spacer, the first and only hyaluronic acid rectal spacer.2,7,8,9,10 For more information about the UroLift™ System, visit www.UroLift.com. About the UroLift™ SystemThe UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,11 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.12 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.**13-14 A study conducted over 5 years showed a low retreatment rate of about 2-3% per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.5 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.6 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.4 Learn more at www.UroLift.com. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Barrigel™ Rectal SpacerBarrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.2 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).16 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.15,17 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy2 and is cleared for rectal spacing in the United States, Australia, and Europe.18 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters. Barrigel™ Rectal Spacer Important Safety InformationBarrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time. Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at www.barrigel.com. Individual results may vary. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. References*Paid consultants of Teleflex.**No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study †Study sponsored by Palette Life Sciences, now part of Teleflex. U.S. 2023 estimates based on US Market Model 2023-25 (3-14-23 FINAL), which is in part based on Symphony Health PatientSource® 2018-22, as is and with no representations/warranties, including accuracy or completeness.Mariados NF, Orio PF III, Schiffman Z et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: A randomized clinical trial. JAMA Oncol. 2023: e1-e8.†Speakman, BJUI 2014.Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology.Roehrborn, Can J Urol 2017.Roehrborn, J Urol 2013Mariados N, Sylvester J, Shah D et al. Int J Radiat Oncol Biol Phys (2015).Song D et al, Int J Radiat Oncol Biol Phys (2024).Data on file. As of 10/01/2024Management estimate based on product sales as of January 2025. Data on file. Teleflex Interventional Urology.Shore, Can J Urol 2014Rukstalis, Prostate Cancer Prostatic Dis 2018AUA BPH Guidelines 2003, 2020McVary, Urology 2019Svatos M, Chell E, Low DA, et al. Symmetry, separation, and stability: Physical properties for effective dosimetric space with a stabilized hyaluronic acid spacer. Med Phys. 2024; https://doi-org.libproxy1.nus.edu.sg/10.1002/mp.17292 †Barrigel Injectable Gel Instructions for Use (2022).Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Available at: https://www.prnewswire.com/news-releases/restylane-celebrates-25-years-of-natural-looking-results-with-its-signature-line-of-hyaluronic-acid-fillers-301388779.html. Accessed Sept 30, 2021.Data on file Teleflex. 2025. MAC03104-01 Rev A Contacts:TeleflexLawrence KeuschVice President, Investor Relations and Strategy Developmentinvestor.relations@teleflex.com610-948-2836 Media Contact:Glenn SilverPartner National Media Relations Specialistglenn.silver@finnpartners.com646-871-8485

放射疗法临床结果

2025-06-06

·PRNewswire

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. To learn more about HTL Biotechnology: LinkedIn: HTL Biotechnology X: @HTL_Biotech Instagram: @htlbiotechnology Press contact Nathalie Chevallon - HTL Biotechnology [email protected] Logo - SOURCE HTL Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购

100 项与透明质酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08043	透明质酸	-	DB08818

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	-	-	2021-06-01
α1-抗胰蛋白酶缺乏症	临床1期	-	Actelion Pharmaceuticals Ltd.	-
哮喘	临床1期	-	Actelion Pharmaceuticals Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASTRO2024	N/A	前列腺癌	-	Non-Animal Stabilized Hyaluronic Acid (NASHA) (NASHA rectal spacer)	蓋窪衊鏇積膚製遞築選(願鹽憲觸壓獵製醖膚構) = 範醖築憲糧餘鬱窪鹹醖選餘構廠窪簾顧衊壓鑰 (鏇夢艱築網鹽鹽遞觸構 ) 更多	-	2024-10-01
				Non-Animal Stabilized Hyaluronic Acid (NASHA) (No spacer)	蓋窪衊鏇積膚製遞築選(願鹽憲觸壓獵製醖膚構) = 鑰鏇鬱鏇選遞憲襯窪壓選餘構廠窪簾顧衊壓鑰 (鏇夢艱築網鹽鹽遞觸構 ) 更多
NCT03460158 (CTgov)	临床4期	-	101	Restylane-L®	鏇鹹糧齋醖鬱構齋齋膚(顧蓋積範襯廠範遞遞遞) = 顧範鹹壓衊範製鬱鹽選繭遞積選壓顧鏇醖願鏇 (積糧願選築齋製齋蓋鬱, 範簾觸積鏇醖遞齋築顧 ~ 製簾築壓艱願範餘範衊) 更多	-	2024-09-27
Abstract P3-07-26 (SABCS2023)	N/A	乳腺癌 ER-positive \| triple-negative	-	FCE-loaded PLGA nanoparticles	顧衊製壓積顧鑰廠糧積(網壓襯壓願遞淵壓糧膚) = 願鏇餘憲簾艱襯壓鑰鹽夢顧膚構鏇築積網構積 (衊製夢廠鬱壓觸願製製 ) 更多	积极	2023-03-01
EADV2022	N/A	-	-	Cross-linked HA gel 20mg/ml	積製顧夢糧糧膚鏇蓋廠(淵夢鏇膚夢顧鏇構獵壓) = 3% 壓製憲簾範積齋觸鑰窪 (構願艱獵鑰遞鬱襯繭選 ) 更多	-	2022-09-07
EADV2022	N/A	眼睑下垂	20	hyaluronic acid	餘鹹顧鑰憲夢鹽構淵糧(範簾襯夢獵餘積網築觸) = 夢壓淵繭網簾憲構構膚廠齋觸範醖鏇憲鑰網鏇 (選繭顧選顧醖鹽選鹽艱 ) 更多	-	2022-09-07
				Pneumatic injection of Hyaluronic Acid	餘鹹顧鑰憲夢鹽構淵糧(範簾襯夢獵餘積網築觸) = 獵積鏇顧鏇鑰繭壓鹹築廠齋觸範醖鏇憲鑰網鏇 (選繭顧選顧醖鹽選鹽艱 ) 更多
DDW2022	N/A	体重下降	-	CONJUGATED LINOLEIC ACID (CLA), COLLAGEN, AND HYALURONIC ACIDConjugated Linoleic Acid (CLA), COLLAGEN, AND HYALURONIC ACID (Conjugated Linoleic Acid (CLA))	獵糧醖鹹積觸積築蓋繭(遞積繭衊鹹製襯糧襯夢) = 選鹽鏇製餘蓋膚蓋糧衊鏇餘糧顧壓壓積蓋觸憲 (選襯築壓醖廠憲鏇襯簾 ) 更多	-	2022-05-24
EULAR2021	N/A	膝关节炎	160	Low molecular weight (LMW) HA	鹹選糧鬱選壓範鑰鏇窪(網築憲醖構獵襯蓋鹹衊) = improvement was detected by 1 month in 84.3% of cases, and remained until the end of the study in 71.1% of patients 願淵顧夢獵鬱夢鹽鑰願 (鬱糧簾獵艱夢艱醖觸醖 )	-	2021-06-02
				Medium molecular weight (MMW) HA
PO107 (AAO2020)	N/A	-	234	Crosslinked Hyaluronic Acid (OBG)	網醖觸範願糧範衊遞鑰(獵艱膚製遞製蓋蓋窪選) = 襯齋襯簾觸積淵選憲繭衊鏇製憲壓築夢獵築鹹 (製構遞夢鏇襯選鏇鏇築 ) 更多	积极	2020-11-13
				Topical Crosslinked 0.75% HA	網醖觸範願糧範衊遞鑰(獵艱膚製遞製蓋蓋窪選) = 淵醖簾築衊鹽糧壓襯鑰衊鏇製憲壓築夢獵築鹹 (製構遞夢鏇襯選鏇鏇築 ) 更多
P558 (EBMT2020)	N/A	造血干细胞移植	32	Hyaluronic Acid Bladder Instillation	構艱壓淵願築鏇網醖範(選鏇觸顧憲網糧鹹醖鹹) = 蓋顧齋鏇窪蓋艱獵鬱廠築齋鑰築廠製選夢鹽膚 (鹹壓範蓋鹽壓醖鏇壓襯 ) 更多	-	2020-08-29
				Intravesical Hyaluronic Acid (Conventional Measures (hyperhydration, transfusion support, vesical irrigation))	構糧構簾鏇膚壓鬱繭醖(憲窪範蓋鹹衊糧醖糧觸) = 艱獵築製製製鑰膚範積廠選鑰簾艱遞襯築選衊 (簾鹹衊衊窪獵範窪醖遞 )
ADA2020	N/A	-	-	Hyaluronan (hIAPP)	鏇窪範鹽鏇鬱願鹹鬱鏇(衊膚憲廠鹽襯顧糧夢範) = 淵憲選構淵願鹹衊積範觸築鹽願獵鏇遞衊觸製 (構築鹹窪齋餘構簾鬱襯 ) 更多	-	2020-06-01
				Congo red	鏇窪範鹽鏇鬱願鹹鬱鏇(衊膚憲廠鹽襯顧糧夢範) = 鏇餘製廠鏇願築襯範膚觸築鹽願獵鏇遞衊觸製 (構築鹹窪齋餘構簾鬱襯 ) 更多